GlassScriptPhysician profile
Kazz Marsey
NPI 1669132569
$7,770.00
in general payments reported to CMS, 2019-2025
51 companies · $1,825 in 2025
The $1,825 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $977 · 2023: $2,589 · 2024: $2,380 · 2025: $1,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,793.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,838.88 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $879.51 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $476.16 | 2022-2025 | |
| Abbvie INC. | $462.69 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $452.44 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.76 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $328.53 | 2022-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $276.86 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.01 | 2022-2024 | Caplyta |
| Ardelyx, INC. | $216.92 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $210.18 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.36 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Otsuka America Pharmaceutical, INC. | $169.39 | 2023-2025 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $165.42 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $129.58 | 2023-2024 | Yupelri |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $108.97 | 2022-2023 | |
| Insulet Corporation | $79.48 | 2023-2025 | Omnipod |
| Sumitomo Pharma America, INC. | $79.25 | 2024 | Gemtesa |
| Astellas Pharma US INC | $70.63 | 2022-2025 | Veozah |
| Amgen INC. | $70.20 | 2024-2025 | Prolia, Evenity, Otezla |
| Grifols USA, LLC | $68.73 | 2025 | Prolastin-C Liquid |
| Antares Pharma, INC. | $61.42 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $61.29 | 2022-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $57.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.97 | 2024 | Camzyos |
| Corcept Therapeutics | $53.79 | 2025 | Korlym |
| Tolmar, INC. | $50.01 | 2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $47.49 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $42.78 | 2024-2025 | Zoryve |
| Dexcom, INC. | $40.25 | 2023-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $39.64 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $39.28 | 2023 | Nexletol |
| Vanda Pharmaceuticals INC. | $36.93 | 2025 | Fanapt, Hetlioz |
| Organogenesis INC. | $29.23 | 2025 | Apligraf |
| Xeris Pharmaceuticals, INC. | $27.53 | 2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $24.75 | 2025 | General - Erectile Dysfunction |
| Daiichi Sankyo INC. | $22.97 | 2023 | Injectafer |
| Ucb, INC. | $22.31 | 2023 | Nayzilam |
| Lundbeck LLC | $21.08 | 2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $17.58 | 2024 | |
| Avanir Pharmaceuticals, INC. | $16.96 | 2022 | |
| Inspire Medical Systems, INC. | $16.49 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $15.90 | 2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $15.65 | 2022 | |
| Exeltis, USA INC. | $15.47 | 2025 | Slynd |
| Viatris Specialty LLC | $14.90 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $14.20 | 2024 | Voquezna |
| Corium, LLC | $13.99 | 2022 | |
| Phadia US INC. | $13.82 | 2024 | Immunocap |
| Lexicon Pharmaceuticals, INC. | $13.44 | 2023 | Inpefa |
| Biohaven Pharmaceutical Holding Company LTD. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kazz Marsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.